Savara Inc. (NASDAQ:SVRA) Q2 2020 Earnings Conference Call - Final Transcript
Aug 06, 2020 • 04:30 pm ET
demonstrate the drug has beneficial effects.
We are in a great position with this program, we believe in Molgradex and came wells in the patients. And the investors on bank capital tell us they also believe in it and importantly our new CMO, Badrul who ran the FDA division responsible for overseeing such therapies also [Indecipherable].
With the ability to apply key learnings from the IMPALA 2 protocol, and are incorporating input from the FDA and EMA into the study design. We believe IMPALA 2 has a high likelihood of success. We are strongly positioned to improve on the tasks and exceed expectations in the future.
We are grateful for the loyalty and the patience and support of our current investors. Given what we have with IMPALA 2 a drug that is believed to work in a study that's about start. And not to even mention our other phase III top-line programs. We feel the Savara investment thesis is strong and poised to grow stronger still.
As always, we thank you for your support. And we look forward to keeping you updated as milestones met. On that note, I would like to inform you that we will be transitioning away from quarterly call such as this way. And instead, hosting web cross supports throughout the year as needed. And with a frequency that is aligned with our news flow.
We will clearly continue to disclose our quarterly updates for a press release. And we will always alert you to any webcast course one week in advance, so that you can plan accordingly.
Now I will ask Jason to open up the call for analysts questions.